Auna S.A. (AUNA) Earnings Call Transcript
August 19, 2026
Earnings Call Speaker Segments
Thanks, operator. Hello everyone, and I appreciate you being on Auna's conference call, where we will review our second quarter results. I'd like to mention that a webcast presentation accompanies the topics we cover today. Should you want a copy, it's available on our Investor related website, or you may contact Auna's Investor Relations team. Additionally, any variances we discuss will be shown on a year-over-year basis, and for Mexico and Colombia in asset neutral or local currency terms, unless stated otherwise. Moving on to Slide 2. In addition to presenting unaudited figures prepared in accordance with International Financial Reporting Standards, our discussion will address select non-IFRS financial metrics and operating statistics, such as foreign exchange neutral calculations. To gain a complete understanding of these items, investors ought to examine the definitions, along with the metrics and reconciliations, that appear in our earnings press release, which came out yesterday following the close of the market. These non-IFRS financial measures and operating metrics are not meant to be considered in isolation, nor should they serve as a substitute for, or be regarded as superior to, IFRS financial measures; they are provided solely as supplementary information. Before we dive into our prepared comments, I should mention that certain things we say in today's conversation could be forward-looking statements. Those reflect what management currently expects and believes, and they come with various risks and uncertainties. Because of those, actual outcomes might end up differing significantly — including due to factors beyond the company's control. Among these are our target leverage ratio, suppliers and information systems in Mexico, what comes of the initiatives we're implementing in Mexico, Colombia and Peru, the capacity and market that <<inaudible>> was built for, how our strategic plan gets executed, including the <<inaudible>>, and the rollout of the Auna Medical. We're going to talk about our <<inaudible>>, the revenue growth and adjusted EBITDA growth we expect, our guidance for revenue and adjusted EBITDA, and how we'll generate additional growth and lasting value for stakeholders. If you want to hear about the risks that could affect forward-looking statements, please look at the Form 20-F we filed with the U.S. Securities and Exchange Commission, along with our earnings press release. Let's move to Slide 3. On the call with us today are Suso Zamora, who serves as Executive Chairman and President; Gisele Ramy, our Chief Financial Officer and Executive Vice President; and Lorenzo Massart, our Executive Vice President of Strategy and Equity Capital Markets. They're going to walk you through <> Consolidated along with our segment-level financial and operating results for the quarter, plus share where things stand with the strategic growth initiatives we've been pursuing. After that wraps up, we'll take your questions. Suso, over to you.
Thanks, Anie. That's excellent. If we could go to Slide 4 now. The results for our second quarter show commercial momentum that has been sustained throughout Auna's regional Healthcare platform, along with considerable headway on the operational improvements put in place last year, especially in Mexico. Even though we faced margin pressures in every one of our markets this quarter, the business's underlying performance is still solid, and demand across the platform continues to be strong. Consolidated revenue rose 9% in the quarter, driven mainly by volume growth and a better mix of higher complexity services in all three of our markets. Consolidated adjusted EBITDA fell 9%, and on an FX-neutral basis. The decline was driven by short-term margin strain in Mexico and Colombia, along with the impact of penalties we accepted related to billing issues, primarily involving the reconciliation of receivables from the prior year in Peru. During the quarter, Mexico saw an acceleration in volume recovery, as surgeries climbed 7% while oncology chemotherapies and radiotherapies rose 20% compared with the first quarter of 2026. Those gains reflected the continued advantages of better tier classifications negotiated with major insurers, as well as growth in Auna's Oncology services. Revenues also received a boost from favorable pricing in high complexity care and stronger economics under our new ISSTELEON contract, which together contributed to a 4% increase. In Peru, we saw revenue increase by 8%, driven largely by a larger average ticket and ongoing growth in membership. Consistent with Auna's business model, an uptick in high complexity surgeries also helped drive gains during the quarter, along with greater penetration in the B2B market. Turning to Colombia, volumes and capacity utilization rose for a second quarter in a row, which helped push adjusted EBITDA up 18% sequentially. Thanks to the cash the business generated, our leverage fell to 3.6x compared with the first quarter of 2026. Beyond that, we further bolstered our cash position during this quarter. Compared to where we ended 2025, our cash balance rose 43%, while free cash flow climbed 181% versus the same period last year. That shows the tight cash discipline we continue to apply throughout the owners regional platform, helped by improved collections in Colombia. Turning to Slide 5. Despite solid revenue gains and positive cash flow from our platform, consolidated adjusted EBITDA came in lower, largely because of what we're putting into Mexico's medical and leadership talent to support growth, along with the billing reconciliations in Peru. The bottom part of the slide indicates that capacity utilization for our healthcare services rose 2.3 percentage points year-to-date, reaching 66%, and was up 2.8 percentage points on a sequential basis. Turning to Auna's Insurance segment, membership numbers continue to climb, rising 6% during the quarter. On top of that, MLR held steady at roughly 50%. If we move to Slide 7, we can examine Mexico's results more closely; within Mexico, the quarter-over-quarter growth in patient volumes was once again driven by high complexity services, especially oncology surgeries, which posted gains of 7% and 20%, respectively. Oncology continued its outstanding momentum, with revenues climbing 110% versus the first quarter of 2025 and 6% on a sequential basis. In September, Auna will bring online an Elekta EVO linear accelerator in Monterrey. These rank among the most advanced linear accelerators available for radiology, enabling us to deliver best-in-class care to patients. Improved decision onboarding and productivity contributed to the quarter's growth as well. Other factors driving expansion included our ISSTELEON B2G contract, surgical and hemodynamics bundles, plus out-of-pocket income, and all of these combined to lift Mexico to 4% revenue growth. Revenue also climbed 5% versus the prior quarter, while adjusted EBITDA increased 3%; on a year-over-year basis, adjusted EBITDA declined 16%, largely due to our continued investments in medical and leadership talent. Quarterly growth was dampened by the April Easter holidays and by Mexico's value-added tax on insurance; volumes and revenue rebounded noticeably across May and June, and we expect stronger year-over-year growth during the second half of the year. Another priority for Auna is driving down variable costs in Mexico. Beyond the improvement it brings to margins, that work strengthens what we offer to the nation's largest insurers and remains a key source of competitive advantage for Auna. Turning to Slide 8. During the quarter, revenue growth in Peru came from both OncoSalud and Healthcare Services. Price adjustments, an improved service mix, and a 6% increase in memberships all contributed to an 11% rise in OncoSalud's revenue. A new B2B plan that covers 7,000 setup employees is another factor supporting membership growth, reflecting how far we've come in sharpening commercial execution within the large corporate segment. Momentum in healthcare services is positive as well. During this quarter, emergency treatments increased 9%, and they were up 14% compared with the first quarter of 2026, thanks to new commercial programs focused on corporate policyholders. Utilization of capacity reached 83%. Although Peru brought in more revenue and we used more of our capacity, adjusted EBITDA did not change from the same period a year earlier, in part due to penalties we accepted related to billing measures, primarily in <<inaudible>> from receivables in the prior year. Higher costs for B2B onboarded income at onco, incentives to keep physicians, overtime spending, and pharmacy expenses also weighed on underlying profitability. Once the quarter ended, we acquired a new clinical facility, which will add capacity in southern Lima. This project is going to broaden our surgical and chemotherapy offerings, and it will bring in 30 additional beds via a model that's asset-light and cost-efficient. We expect it to be up and running sometime between late 2027 and early 2028. On top of that, we brought in a Versius SP4 Robotic system, which is built to enable minimally invasive work using independent robotic arms along with a laparoscopic method, boosting Auna's abilities in high-complexity surgery. Now let's turn to Slide 9. Over in Colombia, we keep achieving meaningful strides when it comes to diversifying who pays us and growing our risk share agreements. Those contracts now make up 24% of our revenue, compared with 14% during the same period last year, and they span over 3 million lives. They played a key part in driving our 13% revenue growth, and they're also improving both cash conversion and predictability. At the same time, the share of revenue coming from intervention payers dropped to 12%, down from 18% a year earlier, and the increase we saw from private payers was enough to more than make up for that decline. Capacity utilization also continued to climb as patient volumes grew, hitting 79.2% compared with the same quarter last year, and that level is now above where it stood prior to the rebase intervention. Adjusted EBITDA was down 12% year over year, a decrease reflecting higher costs associated with added complexity, the increased minimum wage, investments in talent, and a larger portion of risk sharing agreements. Despite that, the sequential trend clearly improved, with adjusted EBITDA rising 18% and margins expanding 1.7 percentage points. Our expectation is that contractual price increases during the second half will mostly counterbalance these cost pressures and underpin robust EBITDA growth. Lastly, having intentionally held back on growth capital in Colombia across the last 2 years, we are starting to invest in a selective way once more given the recent elections and the new administration's plans. We see appealing opportunities taking shape in the market and aim to put ourselves in position to seize them. After the quarter closed, and in response to the new government's emergency stabilization plan, we added operating capacity at our <<inaudible>> Facility in Monteria, bringing in 18 adult ICU beds along with 24 hospitalization beds. That capacity was mostly ready to operate, so only minimal incremental CapEx was required, and we expect it to be highly accretive through the rest of the year. We also spot further chances to keep growing capacity in a way that is similarly efficient with capital. On that note, I will hand the call to Gisele, who will walk through our results in more detail.
Thanks, Suso. I'll start my review on Slide 11, where we lay out the key revenue drivers for the second quarter. In Mexico, the expansion came mainly from high complexity volumes, with Surgery volumes up 6% and chemotherapy plus radiotherapy volumes up 86% versus the prior-year period. Peru's top line growth came from new member of <<inaudible>>, among them the 7,000 employees Suso mentioned a moment ago. Commercial initiatives were another important driver, lifting patient volumes across our healthcare network and shifting the mix further toward high complexity surgeries. In Conombia, fresh relationships with private payers and risk sharing models have taken the place of revenue from the intervene payers we have been steadily exiting. Private payer revenues rose 17% compared with the same period last year and made up 18% of Colombia's revenues in the second quarter. On top of that, risk-sharing contracts now account for 24% of total revenue in Columbia. Now let's look at EBITDA on Slide 12. The drop in adjusted EBITDA mirrors the lower contribution margins tied to Mexico's service mix plus our growth investments in talent. For Colombia, it mirrors the variable cost of stabilizing our new risk-sharing contracts together with statutory wage increases, and we also saw higher pharmacy costs tied to the period service mix in Mexico and the onboarding of new B2B contracts in Peru. Billing impacts in Peru were another factor, mainly linked to prior year billing matters; we are actively shortening our internal billing cycle so these impacts shrink going forward, and we also expect to wrap up all open negotiations tied to reconciliations of previous years during 2026. Over the second half of this year, we expect adjusted EBITDA to keep improving sequentially; the drivers will be rising volumes and operational progress in Mexico, interactional price adjustments fully taking effect to lift profitability in Colombia, the stabilization of new risk sharing contracts in Colombia, and new B2B compress in OncoSalud, Peru. Let's turn now to adjusted net income on Slide 13. Adjusted net income came to PEN 40 million in the second quarter. The swing versus the comparable period of last year was mainly driven by a decrease of PEN 61 million FX gains after we reset the level of our FX hedges tied to our debt at the end of 2025, which should help cut FX volatility going forward. Although operating profit fell, income taxes dropped by a larger proportion, more than offsetting that decline. Let's now go to Slide 14, please. Cash flow generation remains a key highlight this quarter. Net cash from operating activities hit PEN 441 million across the first 6 months of the year, up 45% year-over-year, while free cash flow rose by 181%. That strong cash flow growth came mainly from better working capital management, higher collections recovery, several supply chain financing initiatives rolled out across Auna's regional platform; and lastly, the utilization of tax credit. We likewise saw a big boost to our cash balance, which is up 43% from the close of 2025. Organic maintenance CapEx was more or less unchanged compared with a year earlier, but money spent during the period on <<inaudible>> CapEx payments came in a bit lower than year-to-date 2025, because finance leases during year-to-date 2026 covered a bigger share of acquisitions. Let's move on to Slide 15 now; thanks to the cash we brought in this quarter, a reduced net debt level drove a sequential improvement in our leverage ratio. This pattern, together with the better adjusted EBITDA we anticipate for the second half of the year, means we foresee leverage continuing to improve by year-end, bringing us nearer to our medium-term goal of 3x net debt to EBITDA. I should also note that, on an FX-neutral basis across every currency, our gross debt declined by PEN 43 million compared with the end of 2025. That said, because the Peruvian sol weakened slightly, gross debt on a reported basis rose by PEN 574 million. As the quarter closed, we held PEN 191 million in credit lines, with PEN 125 million of that still available for drawing. One last point about our debt structure: 56% of our loans debt is denominated in local currency. The rest of our debt sits in U.S. dollars, and 85% of that is hedged to the Peruvian sol. That wraps up my review of the quarter. I'll hand the call back to Sosu, who has a few closing remarks before we take questions.
Appreciate that, Gisele. In Peru—our most established market and the regional healthcare platform we operate—we keep showing what a vertically integrated approach can deliver. Our attention stays on care of greater complexity, and we anticipate profitability getting better once the upfront onboarding expenses tied to the new B2B accounts, pharmacy costs included, settle into a normal pattern; when it comes to Colombia, margins should keep climbing across the quarters ahead as contractual price hikes kick in and counterbalance elevated operating expenses, and our risk-sharing agreements keep expanding while offering more predictability. For Mexico, we look for sequential gains to carry on, backed by bringing on highly productive physicians, better tier classifications with the big insurers, and ongoing expansion in oncology plus other high complexity services. Our expansion into Lima Sur has us enthusiastic, as do the additional capacity we've added in Monteria and the new linear accelerator we've brought to Mexico; in our view, these moves will strengthen our competitive edge. Turning to what's next, we're restating our full year 2026 revenue guidance at roughly 12% growth on an FX-neutral basis. Given how the business is performing underneath, we anticipate adjusted EBITDA growth near the bottom of our 10% to 4% guidance range, setting aside the effect of Peru's accepted billing penalties, which mostly stem from billing patterns in the prior year. Beyond that, we expect to keep bringing leverage down through the rest of the year, getting nearer to our goal of under 3x net debt to adjusted EBITDA, even as free cash flow keeps surpassing what we originally projected. What gives us assurance about the underlying outlook is Mexico's robust rebound in patient volumes together with the operational gains we foresee continuing to improve in Colombia. Many thanks, and at this point let's begin the question-and-answer portion of the earnings call.
We've got a couple of things to ask. The first concerns working capital. So we observed that during the opening six months, cash conversion increased significantly. Yet I also noticed that a large portion of that shift stemmed from receivables and payables. So if we strip out any kind of legacy receivable collection, how much of what's left came from normal payment timing as opposed to, say, supplier financing or some other working capital financing arrangement? Also, what was the supplier financing balance as of June — meaning what would DPO be if we remove those programs? And what would first half cash conversion look like on an underlying basis if we factor in the spend-off adjustments? Then the second thing relates to Peru revenue recognition; so in both Q1 and Q2, we recognized deductions tied to prior periods building reconciliation. So have you already modified the methodology and controls you rely on to estimate expected payer deductions, similar to what we see with Brazilian payers, right, the Brazilian provider uses the term clause when revenue is initially recognized — and what evidence makes you confident that the 2026 receivables vintage won't need a comparable retrospective adjustment?
Thanks, Mauricio, and it's good to have your first question, it's turning into a tradition, I appreciate it. And I think both of those questions fall more under your area?
Yes. Great, Suso, thanks. So to address those parts of your question first, from a working capital standpoint, yes, that's right. We've observed significant gains during the first half of this year compared with the same period a year ago. Most of that, on the receivables side, stems from better accounts receivable days. More specifically on the current portion — right, addressing your question about whether it relates to the current portion or the legacy portion. And this relates both to shortening the internal billing cycle in Colombia's case and in Peru's case. Also regarding the full billing cycle in Colombia, where risk-sharing contracts make up a much bigger share, and those get paid far quicker than under the event model. Lastly, since we've been simplifying things from start to finish, we do observe that such gains can hold up over time and will help support the present level of accounts receivable turnover that we're experiencing; so we do view that as sustainable. And regarding accounts payable days, I just wanted to make clear that we've achieved improvements across the past few quarters, as we've noted, especially tied to supply chain financing programs that we've arranged with financial institutions; and those too can hold up over time since we've brought on board multiple suppliers throughout the geographies, and that's enabling us to achieve this gain in account payable days, which, again, we also view as sustainable over time, and I don't believe any adjustments to that are needed. Lastly, working capital also gains from VAT credits that we've utilized specifically in Peru's case, and that has likewise aided working capital turnover. So I think those are a few of the points worth emphasizing. And we do see solid working capital turnover being maintained for the rest of the year. As for the second part of the question concerning billing penalties, specifically in Peru's case, yes, we've seen an elevated level of billing penalties improve compared with what we observed in earlier periods — perhaps to sort of review the factors. We've seen these revenue adjustments essentially stemming from billing penalties, and they're greater than what we've seen historically, as we noted on last quarter's call. This is obviously influenced by a tough situation in which financial strain among Peruvian payers has pushed them to step up enforcement of billing deadlines and settlement terms. We've been actively reducing our internal billing cycle for a while now and bolstering financial controls to remove future penalty exposure. And specifically, we expect any open and ongoing negotiations tied to settlements of billing matters from prior years to wrap up during this year. That's why we do think it's an impact — a short-term impact that will hit 2026. But by next year, going forward, we should have cleared out reconciliations from prior periods. So for 2026, when we strip out that effect, that's the reason we're keeping our adjusted EBITDA guidance where it is. Talks tied to earlier periods are still ongoing right now, which is why that item isn't factored into those figures.
No, I simply wanted to mention, just so it's clear, that this has essentially been a reset. And within our own organization, we've likewise established a very demanding standard — zero tolerance when it comes to service — to reach the point where we're going to have a conversation about payment. So the entire process of how we provide services, develop services, and handle receivables, we altered it substantially. The industry has transformed, and we too have transformed. And I believe this won't be a circumstance that continues beyond 2026.
One more thing on working capital regarding supplier finance — I gather you mentioned that a number of suppliers have been brought on board with that program. Naturally, that helps the cash position, but does it arrive at a cost expense, and is that the reason we're noticing the margin effect there? Are these two things linked?
No, we aren't seeing effects; no supply chain financing programs are affecting our cost structure, as far as we can tell. And clearly, these have come about through extremely tight negotiations and onboarding efforts with the suppliers we work with. So no, we don't observe any cost impact from it.
I don't see any questions coming in through the webcast platform. So I'll allow a minute for your questions to come through. Right now, there's nothing showing up on the webcast. So I'll keep going and hand things over to Suso for his closing comments.
Thanks a lot, Angie. And thanks to all of you. I’d like to wrap up with a few thoughts. Sure, this quarter brought challenges, and challenges of the same kind we’ve encountered before, yet the fundamental strength of our business model holds. The route we’re on toward growth is clear, and our strategic direction hasn’t shifted. We’ve acted decisively to tackle the short-term difficulties we face right now, and we’re set up for growth that can be sustained. Let me say it again. We appreciate your being with us today, and we appreciate your backing and your attention. Our Investor Relations team is here for anything else you’d like to ask; and once more, have a wonderful day.
This concludes today's conference call. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Auna S.A. transcript - plus 132,000+ transcripts from 7,000+ companies, speaker segments and full-text search - through the EarningsAPI REST API or hosted MCP server.
Get an API key View API docs →For developers and AI pipelines
Programmatic access to Auna S.A. earnings transcripts and 132,000+ others is available through the
EarningsAPI REST API and the hosted MCP server.
Quarterly plans from $162 - full transcripts, speaker segments, full-text search,
and the /api/v1/transcripts/recent polling endpoint for ETL pipelines.